?>

Further contract for Cleveland BioLabs

Cleveland BioLabs, who won a DoD contract earlier this year, was awarded a further contract from the US Department of Health and Human Services to work on their drug to counter the effects of radiation exposure. This contract is worth over $13 M and builds on the $9 M one from earlier this year.

For more see Buffalo Business First here.

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter

Perseverance Pays

Cleveland Biolabs who at the beginning of the year failed to win a large contract from DoD for a drug to treat radiation poisoning was rewarded yesterday with another contract. See the article here. A previous post on the matter can be found here. This contract worth about $9 M pales compared to the one awarded previously at $225 M but will help the company move forward with its research. Read more

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter

Osiris defense contract makes company take off

As previously discussed, the contract Osriris won from DoD for a drug to treat radiation damage to the gastrointestinal system has really caused the company and its stock to take off. See previous posts here and here for more detail. The contract could be worth $225 M initially, and if the US Government decides to use it for civilian use the value could be unlimited. See CNNMoney.com for more.

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter

Cleveland BioLabs Loses Out to Osiris For Radiation Treatment Contract

As we reported earlier today, Osiris Therapeutics won a Department of Defense contract to develop a treatment for radiation sickness. Unfortunately, Osiris’s gain was Cleveland BioLabs’ loss. Cleveland’s “shares plummeted nearly 60% after the Buffalo, N.Y., company’s proposed treatment for the gastrointestinal effects of radiation sickness, Protectan CBLB502, wasn’t chosen.” More details at The Street.

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter

>